BioNTech SE (NASDAQ:BNTX) Given Consensus Recommendation of “Hold” by Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $120.40.

A number of research firms have recently issued reports on BNTX. Oppenheimer began coverage on shares of BioNTech in a report on Friday, January 5th. They issued a “market perform” rating on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. The Goldman Sachs Group lowered their price objective on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 28th. HC Wainwright decreased their target price on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Finally, UBS Group decreased their target price on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. US Bancorp DE boosted its position in BioNTech by 8.2% during the first quarter. US Bancorp DE now owns 4,386 shares of the company’s stock worth $749,000 after purchasing an additional 332 shares during the period. BlackRock Inc. boosted its position in BioNTech by 25.9% during the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after purchasing an additional 331,101 shares during the period. Great West Life Assurance Co. Can boosted its position in BioNTech by 522.3% during the first quarter. Great West Life Assurance Co. Can now owns 2,041 shares of the company’s stock worth $371,000 after purchasing an additional 1,713 shares during the period. Cibc World Market Inc. lifted its holdings in shares of BioNTech by 6.4% during the first quarter. Cibc World Market Inc. now owns 2,983 shares of the company’s stock worth $509,000 after buying an additional 180 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of BioNTech by 58.1% in the first quarter. Sei Investments Co. now owns 145,886 shares of the company’s stock valued at $24,882,000 after acquiring an additional 53,595 shares in the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

Shares of BNTX stock opened at $87.89 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.26 and a current ratio of 9.43. The company has a market capitalization of $20.89 billion, a P/E ratio of 21.33 and a beta of 0.23. The company’s 50 day moving average price is $91.86 and its two-hundred day moving average price is $97.80. BioNTech has a 52 week low of $85.21 and a 52 week high of $129.10.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. On average, analysts expect that BioNTech will post -1.67 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.